Aptorum Group Ltd (APM)

APM....................................................https://stockcharts.com/h-sc/ui?s=APM&p=W&b=5&g=0&id=p86431144783

At this moment manipulation on top!

Signal for APM: BUY!
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=APM

Positive signs for APM.
https://stockstotrade.com/news/aptorum-group-limited-apm-news-2025_08_21/

https://www.barchart.com/stocks/quotes/apm/opinion

Buying again

Pump over cash out $3.70s close enough to high then comes the dumpathon

APM.....................................................................p/m

New York State contract a good one. 

$1.6 coming?

APM...........................................................missedthisfish............................................

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

July 16, 2025

Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

Ian Huen, Aptorum's Chief Executive Officer and Chairman, commented, "Following a thorough review and evaluation of ways to continue building value for Aptorum Group’s shareholders, we believe merging with DiamiR, a commercialization-capable company focused on brain health and other significant unmet needs, represents the best path forward for our Company and has the potential to deliver near and long-term value. Our board believes that the combined company will be well-positioned to become a global life sciences company with the capability to generate revenue through biopharma services and offering much needed biomarker panels for complex-biology indications to better characterize patients.”

According to DiamiR’s Chief Executive Officer, Alidad Mireskandari, Ph.D., “Aligning the strategic strengths of the two companies allows us to execute our plans to advance Clinical and Pharma Services solutions for aging-related diseases, such as Alzheimer’s and other neurodegenerative diseases, neurodevelopmental disorders, oncology and autoimmune indications, driving shareholder value and establishing the combined company as a leader in non-invasive, blood-based testing with strong focus on brain health. We look forward to working together with Aptorum’s team and bringing into the combined company our strong assay development, commercialization, reimbursement, and regulatory expertise.”

About the Proposed Transaction, Management & Organization
Under the terms of the merger agreement and subject to stockholder approval, Aptorum Group will re-domicile to the state of Delaware prior to the closing of the merger (“Domestication”), and following the Domestication, acquire all of the outstanding capital stock of DiamiR Biosciences in exchange for a number of shares of its common stock which will represent approximately 70% of the outstanding common stock of Aptorum Group, with the current equity holders of Aptorum Group retaining 30% of the common stock immediately following the consummation of the merger.

The merger agreement has been approved by the boards of directors of both companies, and is subject to stockholder approval of both companies and other customary closing conditions. The proposed merger is expected to close in the fourth quarter 2025.

Following the merger, the combined company will be headquartered in Princeton, New Jersey, and the executive officers are expected to be Ian Huen as Chief Executive Officer, Dr. Alidad Mireskandari as President and Chief Operating officer, and Gary Anthony as Chief Financial Officer. The merger agreement provides that the board of directors of the combined company will be composed of five members, with three members initially designated by Aptorum Group and two members and one board observer initially designated by DiamiR.

The Company will seek its shareholders' approval for the issuance of shares in the merger, as well as other related proposals including the Domestication and a reverse stock split. Completion of the merger is subject to a number of conditions, including, without limitation, approval by Aptorum Group shareholders of both the Domestication and merger share issuance, satisfaction of NASDAQ listing requirements, certain third party consents, a registration statement on Form S-4 for the Aptorum Group shares being issued as merger consideration being declared effective by the Securities and Exchange Commission (the "SEC") and the satisfaction or waiver of other customary closing conditions. Once the Form S-4 has been declared effective by the SEC, the Company intends to set a date for a special meeting for its shareholders to approve the proposals associated with the merger as well as other related proposals as described above, and deliver the final notice for the shareholders meeting to its shareholders.

Hunter Taubman Fischer & Li LLC is acting as legal counsel to Aptorum Group while Ellenoff Grossman & Schole LLP is acting as legal counsel to DiamiR Biosciences. H.C. Wainwright & Co. is acting as financial advisor to DiamiR in connection with the merger.

About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com.

DiamiR Biosciences
DiamiR is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA/CAP-certified laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR’s proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company's website at www.diamirbio.com and connect with DiamiR on LinkedIn.

https://ih.advfn.com/stock-market/NASDAQ/aptorum-APM/stock-news/96441110/aptorum-group-limited-and-diamir-biosciences-enter

$APM

Regardless a sweet day trade!

Computer generated wash trading, brazen illegal manipulation of the stock price. The O/S here is 3.8M, already traded 15 times over at 10:15. Don't get trapped with grossly overpriced stock when they turn the computers off.

Out*

It with $90 profit 🙄🙄

I'm in for $500 at 4.95 

APM....................................missedthisfish..................glta

2m float power live from Singapore... . Before the Merger Agreement was terminated, we determined it was best to focus all of our attention and resources on completing the Merger and therefore paused the majority of our R&D activities during that time; following the termination of the Merger Agreement in the fourth quarter of fiscal 2024, we determined that searching for other business combination opportunities could maximize shareholder value, and our R&D activities remain suspended.


Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research

$6.26 +358%

What with APM explosion premarket with no news?yet

Supersize special $6s 

Cash out $4.08 just for you lol

3.80s cash out time

APM: WOW!!! (Loaded all your picks into Watch!!)

apm.....................................nicecatch

2.64

$2.30s

$2.50s 

APM show and tell $3.03

APM under $10

#APM 🔥 move big monday! See the analysis! $APM

Have I told you today yet that I love you?..............lolol

Z

O.K., Capt. Tim!!

THANK YOU , WELL RECEIVED! WELL CALCULATED AND WILL FOLLOW THROUGH ACCORDINGLY

APM: King Zardiw The Great!!! THANKS, Homeboy!!!

$APM Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z

Shorting into gap fill

APM: If any IHub'er DIDN'T make some bank behind THIS cute puppy today, well, then get some stock-trading COUNSELING from Tim Sykes, or SOMEBODY!!!

Heck, much better CALL LETTERS for this stock would be ATM, instead of silly APM!!!

Time for another rinse

I’m ready to short this time but I won’t rush it,

Wow lol

dilution caught some fish

Waking up

APM share offering will be next event!

Lower prices!

Shaking The Tree At This Moment!

$APM It looks like this can really run based on the chart and what we've seen today! Around 1100% up in one day at a certain point!. https://schrts.co/vxymKNuf

That's what we want on our every trade!

Let's see if there'll be a continuation run tomorrow, usually it can last a few days or more, if more exciting news keep coming in.
What a run! Low float!

Good play today kids

I've been buying APM from $1.44 to $1.83 3,400 shares I bailed between $16.40 & $15.73 one of my best trades in a while!!
The long wick on today's candle looks like further retraction! I could be wrong, good luck to all!!